.svg){kind=icon}
Cell & Gene Therapy
Access new resources for advanced therapy development, from candidate identification through market authorization.
Infographic
MRD as a Primary Endpoint for Accelerated Approval in Multiple Myeloma
Jun 12, 2026
FDA draft guidance on minimal residual disease (MRD) is paving the way towards accelerated approval pathways in multiple myeloma. This infographic outlines key implications for trial design, endpoint strategy, and assay validation to help sponsors advance development with greater speed and confidence.
Related solutions
Patient Recruitment
Predict enrollment more accurately and increase the number of patients per site using data-driven patient recruitment solutions.